Clinical trials for next-generation drugs should be patient-centric – STAT
In designing next-generation clinical trials, it is important to emphasize the broader needs of the patients taking part in them.
Related Articles
How a hidden brain circuit fuels fibromyalgia, migraines, and PTSD
What if your brain is the reason some pain feels unbearable? Scientists at the Salk Institute have discovered a hidden brain circuit that gives pain…
A 37,000-Year Chronicle of What Once Ailed Us
In a new genetic study, scientists have charted the rise of 214 human diseases across ancient Europe and Asia.
Isomorphic Labs has grand ambitions to ‘solve all diseases’ with AI. Now, it’s gearing up for its first human trials
“One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for…
Claims of Microsoft’s ‘super-intelligent’ AI diagnosis agent miss the mark, say experts
Hype around a Microsoft AI agent’s ability to diagnose difficult cases misses the mark and overlooks real innovation, experts say.
Single-cell transcriptomic and chromatin dynamics of the human brain in PTSD
Nature – A comprehensive analysis of the cell-specific molecular regulatory mechanisms underlying post-traumatic stress disorder in the human prefrontal cortex.
AI-powered nudges for chronic disease care need emotional intelligence
Emotionally intelligent AI can generate trust, motivate action, elevate the relationship between patients and their care teams, and drive meaningful change.
What David Baker’s AI biotech unicorn Xaira has been up to
This is the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to AI in health care and medicine.
Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine) | Journal of General Physiology | Rockefeller University Press
The development of analgesic drugs targeting sodium channels NaV1.7 and NaV1.8 is described. FDA approval of the NaV1.8 antagonist suzetrigine presages an
Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain
Pain and Therapy – There is a high unmet need for safe and effective non-opioid medicines to treat moderate to severe pain without risk of…
UK watchdog fines 23andMe for ‘profoundly damaging’ data breach
The fine comes as the DNA testing firm, which filed for bankruptcy in March, is set to be sold to a new owner.